Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals

AIDS

Volumn 11, Issue 2, 1997, Pages 169-175

  Phillips, Andrew N ^a   Eron, Joseph ^b   Bartlett, John ^c   Kuritzkes, Daniel R ^d   Johnson, Victoria A ^e   Gilbert, Carol ^f   Johnson, Judy ^f   Keller, Amy ^f   Hill, Andrew M ^g  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f GLAXOSMITHKLINE   (United States)

^g GLAXOSMITHKLINE   (United Kingdom)

Author keywords

AIDS; CD4 count; HIV RNA; Lamivudine

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; LAMIVUDINE; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031036812     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199702000-00006     Document Type: Article

References (41)

1. Wei X, Ghosh SK, Taylor MF, et al.: Viral dynamics in HIV-1 infection. Nature 1995, 373:117-126.
2. Ho DD, et al.: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
3. Choi S, Lagakos SW, Schooley RF, Volberding PA: CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med 1993, 118:674-680.
4. O'Brien WA, Harligan PM, Martin D, et al.: The relationship of treatment-induced changes in plasma HIV-1 RNA and CD4+ lymphocyte count to progression to AIDS in the Department of Veterans Affairs Zidovudine Study. N Engl J Med 1996, 334:426-431.
5. Daniels MJ, Hughes MD: Bivariate meta-analysis of potential surrogate markers. Stat Med 1997 (in press).
6. De Gruttola V, Fleming T, Lin DY, Coombs R: Validating surrogate markers -are we being naive? J Infect Dis 1997 (in press).
7. Lin DY, Fischl MA, Schoenfeld DA: Evaluating the role of CD4 lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trials. Stat Med 1993, 12:835-842.
8. Concorde Coordinating Committee: Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. 1994, Lancet 343:871-881.
9. Heming TR, Neaton JD, Goldman A, et al: Insights from monitoring the CPCRA didanosine/zalcitabine trial. Terry Beirn Community Programs for Clinical Research on AIDS. J Acquir Immune Defic Syndr 1995, 10 (suppl 2):S9-S18.
10. Loveday C, Hill A: Prediction of progression to AIDS with serum HIV-1 RNA and CD4 count. Lancet 1995, 345:790-791.
11. Henrard DR, Phillips IF, Muenz LR, et al.: Natural history of HIV-1 cell-free viraemia. JAMA 1995, 274:554-558.
12. Mellors JW, Kingsley LA, Rinaldo CR, et al.: Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995, 122:573-579.
13. Connor RI, Mohri H, Cao Y, Ho DD: Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in HIV-1 infected individuals. J Virol 1993, 67:1772-1777.
14. Phillips AN, Eron JJ, Bartlett JA, et al.: HIV-1 RNA levels and the development of clinical disease. AIDS 1996, 10:859-865.
15. O'Brien T, Blattner WA, Waters D, et al.: Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Haemophilia Cohort Study. JAMA 1996, 276:105-110.
16. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
17. Yerly S, Kaiser L, Mermillod B, Baumberger C, Hirschel B, Perrin L: Response of HIV RNA to didanosine as a predictive marker of survival. AIDS 1995, 9:159-163.
18. Wathen LK, Nickens DJ, Chuang-Stein CJ, et al.: HIV-1 RNA viral burden at baseline or it's reduction following antiretroviral therapy is highly correlated with reduced HIV-1 disease progression. 3rd National Conference on Human Retroviruses and Related Infections. Washington, DC, January-February 1996 [abstract LB8c].
19. Katzenstein DA, Hammer S, Hughes MD, et al.: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy with HIV infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996, 335:1091-1098.
20. Brun-Vezinet F, for the Delta Virology Group: HIV viral load changes in Delta patients. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoB.292].
21. Salgo M, Beattie D, Bragnian K, et al.: Saquinavir vs. Hivid vs combination as treatment for advanced HIV infection in patients discontinuing/unable to take retrovir. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoB.410].
22. Lalezari J, Haubrich R, Burger HU, et al.: Improved survival and decreased progression of HIV in patients treated with saquinavir plus Hivid. XI International Conference on AIDS. Vancouver, July 1996 [abstract LB.B.6033].
23. Coombs RW, Welles SL, Hooper MD: Association of plasma human immunodeficiency virus type-1 RNA level with risk of clinical progression in patients with advanced infection. J Infect Dis 1996, 174:704-712.
24. Welles SL, Jackson JB, Yen-Lieberman, et al.: Prognostic values of plasma HIV-1 RNA levels in patients with advanced HIV-1 disease and with little or no zidovudine therapy. J Infect Dis 1996, 174:696-703.
25. D'Aquila RT, Hughes MD, Johnson VA, et al.: Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomised, double blind, placebo-controlled trial. Ann Intern Med 1996, 124:1019-1030.
26. Cohen OJ, Pantaleo G, Holodniy M, et al.: Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue. Proc Natl Acad Sci USA 1995, 92:6017-6021.
27. Eron JJ, Benoit SL, Jemsek J, et al.: Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995, 333:1662-1669.
28. 3: a randomized, double-blind, multicenter, controlled trial. Ann Intern Med 1996, 125:161-172.
29. Katlama C, Ingrand D, Loveday C, et al.: Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. JAMA 1996, 276:118-125.
30. Staszewski S, Loveday C, Picazo JJ, et al.: Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. JAMA 1996 276:111-117.
31. Staszewski S, Bartlett J, Eron I, Katlama C, Johnson J, Hill AM: Reductions in HIV-1 disease progression for AZT/3TC relative to control treatment: a meta-analysis. AIDS 1996, 10 (Suppl 2) [abstract OP7.5].
32. Centers for Disease Control and Prevention: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41(RR-17):1-19.
33. Cox DR, Oakes D: Analysis of Survival Data. London: Chapman and Hall; 1984.
34. Altman DG, De Stavola BL: Practical problems in fitting a proportional hazards model to data with updated measurements of the covariates. Stat Med 1994, 13:301-341.
35. Clayton D, Hills M: Statistical Models in Epidemiology. Oxford: Oxford University Press; 1993.
36. SAS Institute Inc: SAS/STAT Users Guide, Version 6. Fourth Edn. Cary: SAS Institute Inc, 1992.
37. Mosier DE: CD4+ cell turnover. Nature 1995, 375:193-194.
38. Sprent J, Tough D: CD4+ cell turnover. Nature 1995, 375:194.
39. Dimitrov DS, Martin MA: CD4+ cell turnover. Nature 1995, 375:194-195.
40. Phillips AN, Sabin CA, Mocroft A, Janossv G: Antiviral therapy. Nature 1995, 375:195.
41. Ho DD, Perelson AS, Shaw CM: HIV results in the frame. Reply. Nature 1995, 375:198.